BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.10 (-10.38%)
Close on Nov 12, 2026Market cap $12.50MP/E –Yield –
BioCardia r&d expenses
Research and development expenses are spending on new products and technology.
BioCardia's R&D Expenses for the twelve months ending Sep 30, 2026 was $4.49M, down 14.4% year over year. For fiscal 2025 it was $4.96M, up 13.1% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $9.81M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.96M | +13.1% |
| FY2024 | Dec 31, 2024 | $4.39M | -43.2% |
| FY2023 | Dec 31, 2023 | $7.73M | -12.5% |
| FY2022 | Dec 31, 2022 | $8.83M | +3.2% |
| FY2021 | Dec 31, 2021 | $8.56M | -12.8% |
| FY2020 | Dec 31, 2020 | $9.81M | +14.6% |
| FY2019 | Dec 31, 2019 | $8.56M | +1.3% |
| FY2018 | Dec 31, 2018 | $8.45M | +45.8% |
| FY2017 | Dec 31, 2017 | $5.80M | +74.1% |
| FY2016 | Dec 31, 2016 | $3.33M | +119.4% |
| FY2015 | Dec 31, 2015 | $1.52M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.24M | +31.9% |
| Q2 FY2026 | Jun 30, 2026 | $893.00K | -34.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.24M | -19.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.13M | -20.3% |
| Q3 FY2025 | Sep 30, 2025 | $936.00K | +0.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.37M | +71.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.53M | +23.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.42M | +22.4% |
| Q3 FY2024 | Sep 30, 2024 | $931.00K | -50.3% |
| Q2 FY2024 | Jun 30, 2024 | $800.00K | -65.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.24M | -47.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.16M | -47.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.87M | -12.7% |
| Q2 FY2023 | Jun 30, 2023 | $2.31M | +0.4% |
| Q1 FY2023 | Mar 31, 2023 | $2.38M | +9.1% |
| Q4 FY2022 | Dec 31, 2022 | $2.20M | +4.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.14M | -4.3% |
| Q2 FY2022 | Jun 30, 2022 | $2.30M | -2.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.19M | +18.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.12M | -9.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.24M | -9.5% |
| Q2 FY2021 | Jun 30, 2021 | $2.36M | +6.2% |
| Q1 FY2021 | Mar 31, 2021 | $1.84M | -33.9% |
| Q4 FY2020 | Dec 31, 2020 | $2.33M | +7.1% |
| Q3 FY2020 | Sep 30, 2020 | $2.47M | +23.3% |
| Q2 FY2020 | Jun 30, 2020 | $2.22M | +0.2% |
| Q1 FY2020 | Mar 31, 2020 | $2.79M | +28.6% |
| Q4 FY2019 | Dec 31, 2019 | $2.17M | -1.6% |
| Q3 FY2019 | Sep 30, 2019 | $2.01M | -11.3% |
| Q2 FY2019 | Jun 30, 2019 | $2.22M | +9.3% |
| Q1 FY2019 | Mar 31, 2019 | $2.17M | +10.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.21M | +24.5% |
| Q3 FY2018 | Sep 30, 2018 | $2.26M | +33.1% |
| Q2 FY2018 | Jun 30, 2018 | $2.03M | +56.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.96M | +89.3% |
| Q4 FY2017 | Dec 31, 2017 | $1.77M | +3.7% |
| Q3 FY2017 | Sep 30, 2017 | $1.70M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.30M | – |
| Q1 FY2017 | Mar 31, 2017 | $1.03M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.71M | – |
See a number that looks wrong?